A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.
Sponsor: Anita Turk
Terminated
Lack of efficacy.
Listed as NCT04534283, this PHASE2 trial focuses on BRAF V600E and Cancer and remains terminated or withdrawn. Sponsored by Anita Turk, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Feb 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE2
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Oct 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Anita Turk
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .